AREAS OF INTEREST FOR RESEARCH AND COLLABORATION

Schrödinger is a technology based pharmaceutical company known for its proprietary physics-based computational platform. Schrödinger’s therapeutics group has developed numerous preclinical and clinical-stage programs and is looking to support translational research in oncology, immunology or rare genetic diseases from breakthrough academic research. This funding mechanism enables successful projects to benefit from unlimited access to Schrödinger’s proven platform and drug design team to advance novel and validated drug targets discovered in academia. Schrödinger will review the submitted proposals for scientific rationale, suitability of the target to their platform, and alignment to their therapeutic mission. Selected proposals will be provided funding up to $250,000 for Year 1. Based on progress, additional funding may be available, especially if a mutual path is clear towards advancing the program.

RESEARCH & DEVELOPMENT PRIORITIES

RESEARCH PRIORITIES
- The target addresses an unmet need in oncology, immunology or a rare genetic disease (other diseases may be considered)
- The mechanism of action is novel and differentiated from current clinical approaches
- Target is druggable with a small molecule

STAGE OF DEVELOPMENT
- Clear scientific rational for modulating proposed target
- Proof of concept studies have validated the target preclinically
- Screening assays are available (not required, but desirable)
- Tool compounds or antibodies are available (not required, but desirable and can accelerate computational validation)
- Biomarkers are available (not required, but desirable)

Additional Information to increase the value of proposal
- Outline of existing data or prior publication
- Achievable milestones in a 1-year timeframe

DEADLINE FOR SUBMISSION: FEBRUARY 18, 2024